硼替佐米、环磷酰胺和地塞米松作为多发性骨髓瘤诱导治疗的II期研究:DSMM XI试验
DSMM XI试验评估VCD方案诱导治疗初治多发性骨髓瘤的安全性和疗效。414例患者接受3个21天周期VCD后行自体干细胞移植,ORR为85.4%,高危与标危细胞遗传学患者ORR无临床相关差异(86.2% vs 84.3%)。中位随访55.5个月,中位PFS 35.3个月,中位OS未达到;高危患者PFS和OS显著缩短。
要点
- VCD诱导后ORR达85.4%,高危与标危细胞遗传学患者ORR无临床相关差异。
- 最常见≥3级不良事件为白细胞减少(31.4%)和血小板减少(6.8%)。
- ASCT后长期随访,高危细胞遗传学与显著缩短的PFS和OS相关。
核心结论
- VCD是有效且可耐受的诱导方案;结果提示VCD诱导高缓解率不依赖于细胞遗传学风险状态,但长期随访后细胞遗传学高危与ASCT后PFS和OS显著降低相关。
研究设计与样本
- II期研究,414例初治多发性骨髓瘤患者接受3个21天周期VCD诱导后行自体干细胞移植。
主要发现
- 最常见≥3级不良事件为白细胞减少(31.4%)和血小板减少(6.8%)。
- 研究者评估的ORR为85.4%;高危与标危细胞遗传学患者诱导后ORR分别为86.2% vs 84.3%,无临床相关差异。
- 113例接受ASCT并纳入前瞻性巩固试验的患者中位随访55.5个月,中位PFS为35.3个月,中位OS未达到。
- 高危 vs 标危细胞遗传学患者中位PFS为19.9 vs 43.6个月(P < 0.0001),中位OS为54.7个月 vs 未达到(P = 0.0022)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We assessed the safety and efficacy of bortezomib, cyclophosphamide and dexamethasone (VCD) induction therapy in previously untreated multiple myeloma patients. A total of 414 patients received three 21-day cycles of VCD prior to autologous stem-cell transplantation (ASCT). Most common grade ≥3 adverse events were leucopenia (31·4%) and thrombocytopenia (6·8%). The overall response rate (ORR) by investigator-based assessment was 85·4%. Most patients (74%) underwent successful central laboratory-based molecular cytogenetic analysis. No clinically relevant differences in ORR post-induction were seen between patients with or without high-risk cytogenetic abnormalities (86·2% vs. 84·3%). Further follow-up data are available for 113 patients receiving ASCT who were included in a prospective consolidation trial (median follow-up, 55·5 months); median progression-free survival (PFS) was 35·3 months and median overall survival (OS) was not reached. In patients with high-risk versus standard-risk cytogenetics, median PFS was 19·9 vs. 43·6 months (P < 0·0001), and median OS was 54·7 months versus not reached (P = 0·0022). VCD is an effective and tolerable induction regimen; results suggest that VCD induces high response rates independently of cytogenetic risk status, but after long-term follow-up, cytogenetic high risk is associated with markedly reduced PFS and OS post-ASCT.
引用
- Einsele H, Engelhardt M, Tapprich C, et al. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. Br J Haematol. 2017. PMID: 28961309. doi:10.1111/bjh.14920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。